-
-
-
-
-
-
-
ENHERTU plus pertuzumab gets FDA breakthrough therapy designation
-
-
-
-
-
-
-
FDA accepts Aldeyra's reproxalap drug application for dry eye disease
-
-
-
-
-
-
-
Silo Pharma completes dosing in PTSD drug safety study
-
-
-
-
-
-
-
ICON ranks top in phase 1 clinical trials benchmarking report
-
-
-
-
-
-
-
Kairos Pharma reports positive safety data from prostate cancer trial
-
-
-
-
-
-
-
Merck launches phase 3 trials for monthly HIV prevention pill
-
-
-
-
-
-
-
Iovance reports 49% response rate for Amtagvi in melanoma study
-
71,212 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.